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1. Introduction 
Prostate cancer is among the most common types of malignancies and causes of cancer-
related deaths in men worldwide (Fitzpatrick, et al., 2009). Primary tumor involvement 
outside the prostatic capsule or relapse following radical prostatectomy results generally 
in incurability (Lassi & Dawson, 2009). Androgen deprivation therapy has progressed 
since attempts in 1941, when surgical castration had been shown to improve outcomes for 
the first time. Palliative treatment consists of hormonal manipulation to deprive the 
cancer cells of androgenic stimulation by orchidectomy or use of LHRH analogs and 
steroidal or nonsteroidal antiandrogens (Kollmeier & Zelefsky, 2008). Although 
continuous androgen suppression therapy (CAS) has been a cornerstone of the 
management of prostate cancer for more than 50 years, controversy remains regarding its 
optimum application. Generally, androgen suppression (AS) is performed as continuous 
treatment, resulting in apoptotic regression of the tumor cells in a high percentage of 
cases. However, surgical or medical castration results in median progression-free survival 
of only 2–3 years, with no other effective treatment left (Mellado, et al., 2009). Responses 
to cytotoxic therapy are low and only recently several studies revealed a possible benefit 
of incorporating chemotherapeutic agents in treatment regimen for prostate cancer 
(Chang & Kibel, 2009). Taxanes like docetaxel and cabazitaxel, therapeutic cancer vaccines 
and newly developed agents targeting androgen receptor signaling are expected to 
improve therapy (Madan et al., 2011). 
Following experimental research using animal models, intermittent androgen suppression 
(IAS) was introduced as new clinical concept, assuming that during limited regrowth in the 
treatment cessation periods tumorigenic cells are residing in an androgen-responsive state 
(Goldenberg, et al., 1995). Since induction of androgen independence may occur early after 
treatment initiation, cessation of antiandrogen therapy prior to this switch is expected to 
maintain the apoptotic potential of the tumor cells and keep them sensitive to retreatment. 
Providing an easy method for selection of the type of treatment and early assessment of 
tumor growth during the off-periods serial serum PSA determinations made IAS feasible. In 
detail, IAS consists of an initial androgen suppression period of up to nine months 
combining LHRH antagonists and antiandrogens, which is followed by treatment cessation 
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until a certain PSA threshold is reached; then, androgen suppression is reinitiated until a 
maximal effect is observed again. In initial pilot trials regrowing tumors of patients 
undergoing IAS were consistently reported to be sensitive over several cycles of androgen 
withdrawal (figure 1).  
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Fig. 1. Schematic model of CAS and IAS. CAS treatment of prostate cancer rapidly results in 
appearance of androgen-insensitive cells and tumor progression within 2–3 years in 
advanced stages. On the contrary, IAS preserves the hormone sensitivity of the cells through 
cycling between androgen suppression and treatment cessation phases in order to prolong 
the time to hormone refractoriness and possibly survival. 
Therefore, the primary goal of IAS has been the prolongation of the hormone-sensitivity of 
the tumors, which in turn has been expected to result in increased survival eventually. 
Based on the available evidence, IAS nowadays represents a valid treatment option for 
patients with nonmetastatic prostate cancer, including those with locally advanced disease, 
either with or without lymph node involvement, and those who relapsed following 
apparently curative treatment. IAS has been researched since the mid-1980s in a number of 
clinical phase II and III trials in an effort to prolong hormone-dependency and reduce 
adverse effects and costs of CAS (Goldenberg, et al., 1995; Bales, et al., 1996; Buchan & 
Goldenberg, 2010, da Silva, 2011). With preclinical evidence suggesting a potential benefit of 
IAS in terms of time to androgen independence, with phase II and phase III studies 
producing optimistic results and with the potential for decreased costs and complications, 
IAS has now become a popular modality of therapy worldwide. 
2. Experimental development of intermittent androgen suppression 
The concept of IAS was experimentally developed using the androgen-dependent Shionogi 
mouse mammary tumor, investigating regular phases of growth, regression and recurrence 
of xenograft tumors during serial transplantation (Bruchovsky, et al., 1985). Since 
postcastrational progression of tumors towards an androgen-independent state appears to 
be linked to the cessation of androgen-induced differentiation of tumorigenic stem cells, it 
was hypothesized that the replacement of androgens at the end of apoptotic regression 
might result in the reappearance of differentiated tumor cells that maintain their apoptotic 
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potential. To determine the effect of intermittent application of androgens on the androgen-
dependent Shionogi carcinoma, the tumor was transplanted into a succession of male mice, 
each of which was castrated when the estimated tumor weight became about 3g. After the 
tumor had regressed to 30% of the original weight, it was transplanted into the next 
noncastrated male (Akakura, et al., 1993). This cycle of transplantation and castration-
induced regression was successfully repeated four times before tumor growth became 
androgen-independent during the fifth cycle (figure 2).  
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Fig. 2. Experimental animal model of IAS using androgen-dependent Shionogi tumor cells. 
Tumor cells are androgen-depleted by castration and, following tumor shrinkage to a 
defined degree, treatment cessation re-establishes a hormone-sensitive tumor. This cycle can 
be repeated four times until androgen-insensitive cells constitute a population of 
approximately 50% of all tumor cells in the fifth cycle and progression to a hormone-
refractory tumor occurs.  
The average duration of one cycle was 30 days and progression to androgen-insensitivity 
was observed after 150 days. After castration, the concentration of testosterone in the tumor 
was demonstrated to decline more rapidly than the dihydrotestosterone levels and 
spontaneous recurrent growth was not accompanied by significant elevation of the whole-
tissue concentration of either androgen. These results suggested that a recurrent tumor may 
contain hormone-sensitive cells, which are capable of resuming growth in an androgen-
depleted environment. The data also imply that progression from the androgen-dependent 
to the androgen-autonomous condition involves the selection and outgrowth of 
heterogeneous hormone-insensitive cells. 
The effects of castration on gene expression were measured in the androgen-dependent 
Shionogi mouse tumor model (Rennie, et al., 1988). During the first 48-72 h after castration, 
the tumor continued to increase its mass, but began to regress at 72-144 h. In the surviving 
cells there were no major decreases in RNA synthesis. Under these conditions, selected 
genes become overexpressed and, in particular, the concentration of the transcripts 
encoding testosterone-repressed prostate message-2 (TRPM-2/clusterin) was enhanced only 
when tumor regression was most evident, i.e. 72-144 h after castration. The TRPM-2 
(clusterin) gene also became expressed constitutively in non-regressing tumors after the first 
and subsequent cycles of androgen withdrawal. TRPM-2 is a membrane-stabilizing protein 
that appears to be involved in limiting the autophagic lysis of epithelial cells during 
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apoptosis and is possibly preserving the nuclear environment, suppressing the lethal effect 
of anti-androgenic treatment (Akakura, et al., 1993). Therefore, tumor progression, 
characterized by the loss of the apoptotic potential, appears to be linked in part to the 
inappropriate activation of the TRPM-2 gene. 
Since postcastrational progression of tumors to an androgen-independent state appears to 
be linked to the cessation of androgen-induced differentiation of tumorigenic stem cells, 
the replacement of androgens at the end of a period of apoptotic regression might result 
in the regeneration of differentiated tumor cells with maintained apoptotic potential. 
(Akakura, et al., 1993). The frequency of androgen-dependent and -independent 
tumorigenic stem cells in parent and recurrent Shionogi tumors was determined with help 
of an in vivo limiting dilution test (Rennie, et al., 1990). When assayed in male hosts a 
marked enrichment of stem cells in the recurrent tumors (1/200 tumor cells) relative to 
the parent tumors (1/4000 tumor cells) was detectable. By measuring tumor takes in 
female mice, a 500-fold increase in androgen-independent stem cells was found in the 
recurrent carcinoma. No enrichment of androgen-independent stem cells was evident in 
regressing parent tumors. This finding implies that the androgen-independent cells that 
survived androgen-withdrawal may result from the ability of a small number of initially 
androgen-independent stem cells to adapt to an altered hormonal environment. These 
results again indicated that the tumor mass mainly consisted of differentiated cells and 
that stem cells are initially androgen-dependent, but the apoptosis-inducing effect of 
androgen withdrawal will be limited to a factor of 100–1000, before compensatory 
adaptive mechanisms lead to progression of stem cells to an androgen-independent state. 
In recurrent tumors the amount of dihydrotestosterone was reduced by approximately 
85% in comparison to the parent tumor and expression of nuclear androgen receptor was 
completely abolished within 24 h after castration (Bruchovsky, et al., 1990). However, later 
on the amount of androgen receptor mRNA in androgen-dependent and -independent 
cells derived from the Shionogi carcinoma was similar, showing no relationship to 
progression (Akakura, et al., 1996). The uncoupling of TRPM-2 expression and apoptosis 
observed in androgen-independent tumor cells implicates that the function of androgen 
receptor becomes more restricted with tumor progression. There is evidence that the 
androgen receptor still plays an important role in progression to the castration-resistant 
incurable state in prostate cancer. While castration proved to be ineffective in castration-
resistant prostate tumors in an animal model, knockdown of androgen receptor was 
demonstrated to decrease serum PSA, inhibit cancer growth and frequently resulted in 
tumor regression (Snoek, et al., 2009). This study provided evidence that elimination of the 
androgen receptor might constitute a promising therapeutic strategy for treatment of 
prostate tumors that had progressed to the castration-resistant state. 
Serial determinations of the proportion of stem cells in the Shionogi tumor revealed a 
constant part during the first three cycles but a 15-fold increase between the third and fourth 
cycles (Rennie, et al., 1994). In the parent androgen-dependent tumor before androgen 
ablation they formed 0.8% of the total stem cell compartment. After the fourth cycle the 
androgen-independent stem cell population increased to 47% and a population of similar 
size was found in the androgen-independent recurrent of the tumor, which was induced by 
one-time castration. Therefore, it was concluded that independent of intermittent or 
continuous androgen withdrawal, conversion to hormone-insensitivity occurs as soon as the 
tumor has accumulated one-third to one-half of the total stem cell compartment with 
androgen-independent cells.  
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The next step included the switch to a human prostate cancer xenograft model using the 
LNCaP androgen-dependent prostate cell line, where serum PSA levels correlated well with 
tumor volume and decreased rapidly after castration, followed by appearance of androgen-
independency after 3-4 weeks (Gleave, et al., 1996). IAS-treated mice were implanted with 
testosterone pellets two weeks after castration and were subjected to cycles of testosterone 
replacement for 1 week and withdrawal for 2 weeks until serum PSA levels returned to 
baseline no longer. IAS therapy prolonged time to androgen-independent PSA production 
3-fold, from an average of 26 days in the CAS group to 77 days in the IAS group. It was 
concluded that IAS in the LNCaP model delayed the onset of androgen-independent PSA 
gene regulation markedly most likely due to androgen-induced differentiation and/or 
downregulation of androgen-suppressed gene expression. In summary, the animal 
experimental data indicated that androgen-dependent tumor xenografts can be subjected to 
several cycles of androgen withdrawal/replacement and revealed prolonged hormone-
dependency compared to continuous androgen suppression. 
3. Clinical development of intermittent androgen suppression 
Since the introduction of PSA screening in the late 1980s, more prostate cancers have been 
detected, and at an earlier stage (Gjertson & Albertsen, 2011). Consequently, the majority of 
prostate cancers are now detected years before the emergence of clinically evident disease, 
which usually represents locally advanced or metastatic cancer. PSA screening has remained 
controversial, because many of the prostate cancers detected are low grade and slow 
growing and will not need aggressive therapy. Prostate cancer is biologically and clinically a 
heterogeneous malignancy and its imaging evaluation will need to be tailored to the specific 
phases of the disease in a patient-specific, risk-adapted manner (Jadvar, 2011). With this 
long natural history and a median survival without treatment that often approaches at least 
15-20 years, many patients will die rather with than of prostate cancer. Approximately one-
third of patients who undergo radical prostatectomy will develop a detectable PSA level 
within 10 years (Tzou, et al., 2011). Biochemical relapse is defined as a rising PSA level in the 
absence of clinical or radiographic evidence of tumor. Management of PSA recurrence is 
controversial, as prostate cancer may take an indolent course, or it may develop 
aggressively into metastatic disease. The only potentially curative treatment for biochemical 
failure after prostatectomy is radiotherapy and the other treatment options include hormone 
therapy or clinical trials of new agents.  
Research on hormonal treatment of prostate cancer over the past 20 years has focused on 
maximizing androgen ablation through combination therapy. This increases treatment-
related side-effects and expenses and fails to prolong time to progression to androgen-
independence (Gleave, et al., 1998, Kollmeier & Zelefsky, 2008 ). Preliminary evidence 
indicates that a low androgen milieu is associated with tumor aggressiveness. Transition to 
androgen-independence is a complex process and involves both selection and outgrowth of 
preexisting androgen-resistant clones as well as adaptative upregulation of genes that 
enable cancer cells to survive and grow after CAS (Corona, et al., 2011). CAS in men with 
prostate cancer increases the risk of osteoporotic fractures, type 2 diabetes and, possibly, 
cardiovascular events (Grossmann, et al., 2011). The benefits of CAS in treating non-
metastatic prostate cancer need to be carefully weighed against the risks of CAS-induced 
adverse events. Management of the metabolic sequelae of CAS includes optimal reduction 
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of cardiovascular risk factors, with particular attention to weight, blood pressure, lipid 
profile, smoking cessation and glycemic control. 
The rationale behind IAS is based on the hypothesis that, if tumor cells, which survive 
androgen withdrawal, are forced into a normal differentiation pathway by androgen 
replacement, their apoptotic potential might be restored and progression to androgen 
independence may be delayed. Furthermore, immediate androgen ablation can be 
accomplished with less side effects and quality of live can be improved in a palliative 
setting. Observations from animal model studies suggest that progression to androgen-
independence involves adaptive responses to androgen deprivation, which seem to be 
delayed by intermittent androgen replacement. Supported by these results, several centers 
tested the feasibility of IAS in non-randomized groups of prostate cancer patients with 
serum PSA as trigger point (Buchan & Goldenberg, 2010).  
For example, in a small pilot trial in four stage C and three stage D patients with prostate 
cancer androgen withdrawal was initiated with cyproterone acetate and diethylstilbestrol 
and then maintained with cyproterone acetate in combination with the LHRH agonist 
goserelin acetate (Akakura, et al., 1993). After 6 or more months of suppression, treatment 
was interrupted for 2-11 months. After recovery of testicular function, androgen-withdrawal 
was resumed when serum PSA increased to a level of about 20 ng/ml. This cycle was 
sequentially repeated to a total of 2-4 times over treatment periods of 21-47 months with no 
loss of androgen-dependence. These early results demonstrate that IAS can be used to 
induce multiple apoptotic regressions of a tumor. 
Overall, these trials suggest that IAS is neither inferior nor superior to CAS, with respect to 
time to castration resistance and cancer-specific survival, but has significant advantages in 
terms of adverse effects, quality of life and costs (Buchan & Goldenberg, 2010). A number of 
unresolved questions remain regarding patient selection for therapy, optimum duration of 
treatment, optimal time point of reinitiation oftherapy after the off-phase and definition of 
progression to castration-resistant disease. In future, the use of second-line drugs during off-
treatment phases holds potential for delaying disease progression in men undergoing IAS. 
In a review data from 19 phase II studies were discussed with respect to PSA values for 
treatment suspension/reinitiation, treatment regimen, cycle lengths, testosterone 
normalization and tolerability. Most trials reported an improvement in quality of life during 
the off-therapy periods. Interim data from 8 phase III trials comparing IAS and CAS were 
found to corroborate the phase II results (Abrahamsson, 2009). Phase II/III data suggested 
that IAS was as effective as CAS but was characterized by better tolerability and quality-of-
life advantages; however, more data are required to determine the effect of IAS on the long-
term complications of androgen deprivation. Disease progression in 96 patients with 
biochemically relapsed prostate cancer under IAS was associated with pretreatment PSA 
doubling time (PSADT) ≥6 vs. <6 months, first off-treatment interval PSADT of ≥3 vs. <3 
months and PSA nadir during the first treatment interval of <0.1 vs. ≥0.1 ng/ml. During IAS 
PSADT became shorter and was associated with testosterone recovery (Keizman, et al., 
2011). The duration of the first off-treatment interval (< or > 40 weeks) was correlated with 
shorter time to hormone-insensitivity and death after adjusting for age, stage, grade and 
PSA at diagnosis (Yu et al., 2010, Sciarra, et al., 2011). 
Few randomized studies compared IAS with CAS for the treatment of advanced prostate 
cancer. Early survival results from phase III trials were limited and inconsistent. Mottet and 
colleagues reported no significant difference between patients receiving IAS and CAS with 
respect to median overall survival and median progression-free survival (Mottet, et al., 2006). 
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In another IAS study, 127 patients from the intermittent arm and 107 patients from the 
continuous arm progressed, with a hazard ratio (HR) of 0.81 (da Silva, et al., 2009). There was 
no difference in survival, with a HR of 0.99. The greater number of cancer deaths in the IAS 
arm (106 vs 84) was balanced by a greater number of cardiovascular deaths in the continuous 
arm (52 vs 41). Side effects were more pronounced in the continuous arm and patients treated 
with IAS reported better sexual function. Median time off therapy for the IAS-treated patients 
was 52 weeks. However, significant differences were reported in one study: de Leval and 
colleagues published that the estimated risk of 3-year progression in CAS patients was 
significantly higher than in the IAS group. This difference was highlighted in patients with a 
Gleason score >6, where the 3-year progression rates were significantly higher in CAS rather 
than in IAS patients (de Leval, et al., 2002). Large phase III clinical trials of intermittent vs 
continuous androgen deprivation in men with metastatic disease or recurrent disease after 
localized therapy were requested for more than 2 decades in order to obtain reliable data for 
the comparative impact of these therapies on quality of life and survival. 
Finally, the Intergroup randomized phase III trial, which compared IAS vs CAS to test for 
non-inferiority of IAS with respect to overall survival was presented in February 2011 
(Klotz, et al., 2011). Eligible men had rising PSA > 3.0 ng/ml >1 year post irradiation that 
was either initial or salvage for treatment of localized prostate cancer. IAS was delivered for 
8 months in each cycle with restart when PSA reached >10 ng/ml in the off-treatment phase. 
Primary endpoint was overall survival (OS); secondary endpoints included time to hormone 
refractory state, quality of live, duration of treatment/non-treatment intervals and time to 
recovery of testosterone and potency. 1,386 patients were randomized to IAS (690) or CAS 
(696) arms and median follow-up was 6.9 years. IAS patients completed a median of 2 x 8 
months cycles (range: 1-9). Median OS was 8.8 vs 9.1 years in IAS and CAS arms, 
respectively, with more disease-related (122 vs 97) in the IAS and fewer disease-unrelated 
(134 vs. 146) deaths in the CAS arm. Time to hormone resistance was statistically 
significantly improved in the IAS arm (HR 0.80, p = 0.024). Time to development of 
castration resistance was close to 10 years and in favour of IAS, but the trial design was 
biased towards IAS. In order to achieve castration resistance status, patients had to be 
being on treatment. Therefore, some patients who had a rising PSA off-treatment may in 
fact have had castration-resistant disease, but treatment had to be restarted and the PSA 
seen to continue to rise before this status could be defined. IAS patients had reduced 
occurrences of hot flashes, but there was no evidence of differences in adverse events, 
including myocardial problems or osteoporotic fractures. Thus, in men with PSA recurrence 
after irradiation IAS is non-inferior to CAS with respect to OS. IAS was suggested to be 
considered as the new standard of care for most patients with PSA recurrence after radical 
surgery. High-risk patients seem to be poor candidates for any type of androgen 
suppression. In summary, it can be concluded from the clinical trials that IAS is neither 
inferior nor superior to CAS, with respect to the end points, namely the time period until 
hormone-resistance as well as cancer-specific survival, but offers significant advantages in 
terms of adverse effects, quality of life and costs. Still, a number of important questions are 
remaining, regarding appropriate patient selection for therapy, optimum duration of 
therapy and exact scheduling of treatment reinstallation after the off-cycle. The off-
treatment periods particularly hold the possibility to apply drugs such as finasteride or 
chemotherapeutics, in order to delay disease progression (Locke & Bruchovsky, 2010). 
Moreover, the study has economic implications: patients in the IAS arm were on therapy 
only 27% of the time, reducing the cost of therapy significantly. 
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4. Side effects of androgen suppression therapy 
The well-known side effects of CAS like sexual dysfunction, hot flushes, fatigue, 
cardiovascular complications, osteoporosis, weight gain and anemia have significant 
implications for quality of life (Malone, et al., 2005; Freedland, et al., 2009; Galvão, et al. 2009). 
Since androgens are essential for the regulation of fat distribution, insulin sensitivity and 
lipid and bone metabolism, recent publications focussed on the concept that CAS may also 
be associated with an increase in overall and in particular cardiovascular morbidity and 
mortality (Corona, et al., 2011). A multivariate analysis by Saigal and colleagues evaluating 
over 22,000 men concluded that patients receiving CAS had a 20% higher risk of 
cardiovascular morbidity (Saigal, et al., 2007). CAS leads to increased incidence of 
osteoporosis and concomitant bone fractures (Kiratli, et al., 2001). Therefore, it was expected 
that off-treatment periods during IAS would allow for recovery of testosterone levels and 
cessation of bone material degradation. With regards to bone loss, a large, retrospective 
study evaluated more than 50,000 men with prostate cancer, showing increased occurrence 
of bone fracture in the CAS group (19.4% vs 12.6%). There was a significant relationship 
between the number of CAS doses and fracture risk (Shahinian, et al. 2005). In the elderly 
population of prostate cancer patients increased incidence of osteoporosis and resulting 
bone fractures are of major concern. Higano and colleagues  observed loss of bone mineral 
density during 9 months of androgen suppression significantly greater than the expected 
0.5%-1% annual loss in IAS; however, interruption of androgen suppression attenuated the 
rate of bone loss without full recovery (Higano, et al., 2004). 
In the study by Malone and colleagues, general loss of potency occurred during the 
treatment period, but was regained by half of the evaluable patients when therapy was 
withdrawn (Malone, et al., 2005). There was no significant overall change in body mass 
index at the end of the treatment periods. Osteoporosis was documented for at least one site 
evaluated in one third of the patients. Quality of life and sexual function seem to follow 
testosterone normalization (Mearini, et al., 2011). Phase II clinical trials demonstrated 
improved sexual function and quality of life in men undergoing IAS (Dawson, 2000). The 
average percentage of time spent off androgen deprivation ranges from 37%-58% and most 
men were responsive to retreatment with hormonal therapy. While IAS seems feasible and 
holds the potential to improve quality of life of the patients, the degree of reversal of the 
long-term side effects of androgen suppression still remains to be confirmed.  
4.1 Bone matrix turnover and androgen suppression therapy 
Our group examined the effect of IAS on bone metabolism by determinations of 
CrossLaps levels, a biochemical marker of collagen degradation in blood samples of 
prostate cancer patients. These measurements revealed that increased bone degradation, 
which was associated with the androgen suppression phases, was rapidly reversed during 
treatment cessation periods, in good agreement with the clinical observations of reduced 
loss of bone mineral density (BMD) in IAS (Theyer, et al., 2010). 140 patients have been 
recruited since 1993, with first patients reaching their seventh treatment cycle (Theyer & 
Hamilton, 1998). All patients with disseminated adenocarcinoma of the prostate fulfilling 
the inclusion criteria of a histologically confirmed tumor, stage ≥T2, not having received 
pretreatment by hormone ablation or chemotherapy and PSA >6 ng/ml were recruited for 
a nonrandomized open IAS trial consisting of an initial 8 months course of androgen 
suppression (goserelin acetate/Zoladex® and cyproterone acetate/ Androcur®), followed 
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by treatment cessation and resuming of the therapy upon increases of PSA >4 and >20 
ng/ml, respectively. Serum testosterone was measured using an ELISA assay (Biomar 
Diagnostics, Marburg, Germany) according to the manufacturer´s instructions. PSA was 
determined by the microparticulate enzyme immunoassay (MEIA, AxSYM PSA assay, 
Abbott, USA). CrossLaps ELISA was obtained from Nordic Bioscience Diagnostics, 
Herlev, Denmark, and used according to the manufacturer´s instructions (Rosenquist, et 
al., 1998). This assay is used for follow-up of anti-resorptive treatment of patients with 
metabolic bone diseases (Okabe, et al., 2004). 
Amino-terminal propeptide of type I procollagen (PINP)  and PSA were determined using 
the Elecsys 2010 Chemistry Analyzer (Roche Diagnostics, Vienna, Austria). All patients 
(n=75; mean age ±SD: 68±7 years, range: 53-84 years) exhibited progression of disease 
without metastases following radical prostatectomy and/or irradiation therapy. The lengths 
of the treatment cessation periods (mean ±SEM) for the respective off-treatment cycles (I–VI) 
in months were: 16±2 (n=75), 10±1 (n=31), 8±2 (n=18), 8±1 (n=12), 10±2 (n=8), 7±6 (n=2), 
respectively. The first treatment cessation period (PI) was significantly longer compared to 
the following breaks, which were not significantly different among each other. Individual 
time courses of testosterone and CrossLaps for a representative patient and four IAS cycles 
is depicted in figure 3A.  
CrossLaps are elevated during androgen suppression phases indicating bone matrix 
degradation and normalize during treatment cessation periods on a regular basis (Theyer, 
et al., 2010). After a prolonged time without androgen suppression, CrossLaps values 
exhibited a gradual increase, most likely due to regrowth of the tumor (data not shown; 
Nguyen-Pamart, et al., 1997). Time courses of PINP and PTH were compared with PSA 
during the same IAS cycles in further measurements (figure 3B). The results show that 
PINP is a suitable alternative parameter for the assessment of bone matrix turnover 
during androgen suppression phases that are accompanied by low PSA levels. The 
parallel course of blood PTH indicates a participation of this hormone in androgen 
suppression-induced bone loss. This finding corroborates reports of decreased loss of 
BMD in bone scans in prostate cancer patients under IAS therapy. Since pretreatment 
concentrations of CrossLaps were restored within several months of therapy cessation 
and mean duration of the off-treatment periods ranged from 8–16 months in our patients, 
this protective effect of IAS is expected to be effective for several treatment cycles (Theyer, 
et al., 2010). The bone matrix synthesis product PINP was used to assess bone turnover in 
metastatic prostate and breast cancer among other malignancies (Jung, et al., 2011; 
Koopmans, et al., 2007; Pollmann, et al., 2007). Studies in metastatic prostate cancer 
patients showed that both PINP and ICTP (carboxy-terminal telopeptide of type I 
collagen) were most indicative of predicting metastatic progression and skeletal 
complications, respectively. Although androgen deprivation has been associated with 
bone loss in patients with prostate cancer, its mechanism remains unclear. The growth 
hormone (GH)/insulin-like growth factor-1 (IGF-1)/parathyroid hormone (PTH) axis that 
plays a critical role in bone synthesis was investigated during CAS (Isahaya, et al., 2010). 
PTH is secreted by the chief cells of the parathyroid glands as a polypeptide containing 84 
amino acids and effects to increase the concentration of calcium in blood (Poole & Reeve, 
2005). The serum PTH level was reduced after CAS by approximately 25% compared with 
baseline levels, concomitant with increases of bone resorption markers like blood and 
urinary N-telopeptides (NTx), in good agreement with our measurements during 
androgen suppression in IAS cycles.  
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Fig. 3. (A) Individual time courses of testosterone and CrossLaps levels for a representative 
patient under IAS. Values cover androgen suppression phases (I–IV) and treatment cessation 
periods (I/P-IV/P). (B) Time courses of PSA, PINP and PTH are shown for the same patient. 
4.2 Anemia and intermittent androgen suppression 
Anemia was previously reported as a common side-effect of CAS. In an IAS study involving 
95 patients receiving 245 cycles the median duration of resting periods was 8 months and 
median time to treatment failure 47 months (Malone et al., 2005). Testosterone recovery 
during treatment cessation was observed in 60% of cycles with mild anemia, which was 
more frequently detected in successive cycles (33%, 44% and 67%). Thus, the observed 
anemia (hemoglobin level of < 30 g/l) was normochromic, normocytic, temporally related to 
the initiation of CAS and usually resolved after discontinuation of therapy in half of the 
cases. The improvement in hemoglobin during the off-treatment intervals probably 
contributes to improvements in the sense of well-being and vitality in these patients.  
We collected data regarding anemia in our prostate cancer patients and a typical course of 
erythrocyte count, hemoglobin content and hematocrit is shown in figure 4. The data show 
that small decreases and increases in erythrocyte parameters coincide with IAS phases and 
levels of PSA. Such determinations can be used to assess the extent of anemia and the 
impact of treatment cessations on erythropoiesis. 
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Fig. 4. (A) Time courses of testosterone and PSA, (B), hemoglobin and erythrocyte count and 
(C) and hematocrit  are shown for 3 cycles of IAS for a typical prostate cancer patient.  
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5. Conclusions 
In the past 25 years, IAS has developed from an unproven theoretical framework to a 
promising therapeutic option for subgroups of prostate cancer patients equal to CAS in 
respect to overall survival. Many questions in regard to the most suitable patient population 
and the optimal application of IAS remain to be investigated. With the exception of the 
frequency of hot flashes the improvement of other side effects of androgen suppression by 
intermittent therapy needs further careful assessment. This can be supported by 
determination of laboratory parameters of bone matrix turnover, blood chemistry and lipid 
profiles and correlation with the clinical characteristics. Last but not least, the reduced costs 
of intermittent therapy are expected to promote a more general application. 
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